nodes	percent_of_prediction	percent_of_DWPC	metapath
Gefitinib—Bosutinib—TLK1—salivary gland cancer	0.0211	0.608	CrCbGaD
Gefitinib—Bosutinib—MAP2K2—salivary gland cancer	0.0136	0.392	CrCbGaD
Gefitinib—CSNK1E—parotid gland—salivary gland cancer	0.00844	0.0492	CbGeAlD
Gefitinib—IRAK4—parotid gland—salivary gland cancer	0.0083	0.0484	CbGeAlD
Gefitinib—CSNK1E—saliva-secreting gland—salivary gland cancer	0.00808	0.0471	CbGeAlD
Gefitinib—IRAK4—saliva-secreting gland—salivary gland cancer	0.00795	0.0464	CbGeAlD
Gefitinib—ERBB3—saliva-secreting gland—salivary gland cancer	0.0078	0.0455	CbGeAlD
Gefitinib—MKNK2—parotid gland—salivary gland cancer	0.00774	0.0451	CbGeAlD
Gefitinib—MKNK2—saliva-secreting gland—salivary gland cancer	0.00741	0.0432	CbGeAlD
Gefitinib—ERBB3—connective tissue—salivary gland cancer	0.00716	0.0418	CbGeAlD
Gefitinib—MKNK2—connective tissue—salivary gland cancer	0.00681	0.0397	CbGeAlD
Gefitinib—ERBB3—epithelium—salivary gland cancer	0.0068	0.0397	CbGeAlD
Gefitinib—MKNK2—epithelium—salivary gland cancer	0.00647	0.0377	CbGeAlD
Gefitinib—MAP2K5—parotid gland—salivary gland cancer	0.00562	0.0328	CbGeAlD
Gefitinib—SBK1—lymph node—salivary gland cancer	0.00555	0.0323	CbGeAlD
Gefitinib—MAP2K5—saliva-secreting gland—salivary gland cancer	0.00538	0.0314	CbGeAlD
Gefitinib—IRAK4—lymphoid tissue—salivary gland cancer	0.00534	0.0312	CbGeAlD
Gefitinib—ERBB3—lymphoid tissue—salivary gland cancer	0.00524	0.0305	CbGeAlD
Gefitinib—MKNK2—lymphoid tissue—salivary gland cancer	0.00498	0.029	CbGeAlD
Gefitinib—MKNK1—lymphoid tissue—salivary gland cancer	0.00492	0.0287	CbGeAlD
Gefitinib—CHEK2—lymph node—salivary gland cancer	0.00483	0.0282	CbGeAlD
Gefitinib—STK10—lymphoid tissue—salivary gland cancer	0.00405	0.0236	CbGeAlD
Gefitinib—EGFR—lymph node—salivary gland cancer	0.00319	0.0186	CbGeAlD
Gefitinib—CSNK1E—lymph node—salivary gland cancer	0.00306	0.0179	CbGeAlD
Gefitinib—IRAK4—lymph node—salivary gland cancer	0.00301	0.0176	CbGeAlD
Gefitinib—ERBB3—lymph node—salivary gland cancer	0.00296	0.0172	CbGeAlD
Gefitinib—MKNK2—lymph node—salivary gland cancer	0.00281	0.0164	CbGeAlD
Gefitinib—IRAK1—lymph node—salivary gland cancer	0.00281	0.0164	CbGeAlD
Gefitinib—MKNK1—lymph node—salivary gland cancer	0.00277	0.0162	CbGeAlD
Gefitinib—ABCG2—parotid gland—salivary gland cancer	0.00273	0.0159	CbGeAlD
Gefitinib—ABCG2—saliva-secreting gland—salivary gland cancer	0.00262	0.0153	CbGeAlD
Gefitinib—CYP1A1—parotid gland—salivary gland cancer	0.0026	0.0151	CbGeAlD
Gefitinib—STK10—lymph node—salivary gland cancer	0.00228	0.0133	CbGeAlD
Gefitinib—CYP1A1—epithelium—salivary gland cancer	0.00217	0.0126	CbGeAlD
Gefitinib—MAP2K5—lymph node—salivary gland cancer	0.00204	0.0119	CbGeAlD
Gefitinib—ORM1—lymph node—salivary gland cancer	0.00166	0.00966	CbGeAlD
Gefitinib—ALB—lymph node—salivary gland cancer	0.00145	0.00847	CbGeAlD
Gefitinib—ABCB1—epithelium—salivary gland cancer	0.00113	0.00657	CbGeAlD
Gefitinib—ABCG2—lymph node—salivary gland cancer	0.000993	0.00579	CbGeAlD
Gefitinib—CYP1A1—lymph node—salivary gland cancer	0.000942	0.0055	CbGeAlD
Gefitinib—ABCB1—lymphoid tissue—salivary gland cancer	0.000868	0.00506	CbGeAlD
Gefitinib—ABCB1—lymph node—salivary gland cancer	0.000489	0.00285	CbGeAlD
Gefitinib—IRAK1—Signaling Pathways—FBXW7—salivary gland cancer	0.000102	0.000129	CbGpPWpGaD
Gefitinib—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—salivary gland cancer	0.000102	0.000128	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—NUP62—salivary gland cancer	0.000101	0.000127	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—ST3GAL4—salivary gland cancer	0.0001	0.000126	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—VCAN—salivary gland cancer	0.0001	0.000126	CbGpPWpGaD
Gefitinib—EGFR—Disease—JAG1—salivary gland cancer	9.98e-05	0.000126	CbGpPWpGaD
Gefitinib—EGFR—Disease—FGFR4—salivary gland cancer	9.93e-05	0.000125	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—PTEN—salivary gland cancer	9.93e-05	0.000125	CbGpPWpGaD
Gefitinib—ERBB3—Disease—NOTCH1—salivary gland cancer	9.91e-05	0.000125	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PYGB—salivary gland cancer	9.88e-05	0.000125	CbGpPWpGaD
Gefitinib—EGFR—NGF signalling via TRKA from the plasma membrane—HRAS—salivary gland cancer	9.88e-05	0.000124	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PHGDH—salivary gland cancer	9.85e-05	0.000124	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—MARCKS—salivary gland cancer	9.78e-05	0.000123	CbGpPWpGaD
Gefitinib—EGFR—Disease—FBXW7—salivary gland cancer	9.77e-05	0.000123	CbGpPWpGaD
Gefitinib—IRAK4—Innate Immune System—HRAS—salivary gland cancer	9.77e-05	0.000123	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—CREBBP—salivary gland cancer	9.73e-05	0.000123	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—MARCKS—salivary gland cancer	9.69e-05	0.000122	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—CDH1—salivary gland cancer	9.66e-05	0.000122	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PYGB—salivary gland cancer	9.65e-05	0.000122	CbGpPWpGaD
Gefitinib—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—salivary gland cancer	9.55e-05	0.00012	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—ST3GAL4—salivary gland cancer	9.48e-05	0.000119	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—EP300—salivary gland cancer	9.47e-05	0.000119	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—FGF16—salivary gland cancer	9.42e-05	0.000119	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—CREBBP—salivary gland cancer	9.3e-05	0.000117	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—AQP1—salivary gland cancer	9.11e-05	0.000115	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—NOTCH1—salivary gland cancer	9.11e-05	0.000115	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PYGB—salivary gland cancer	9.09e-05	0.000115	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PYGB—salivary gland cancer	9.01e-05	0.000114	CbGpPWpGaD
Gefitinib—ERBB3—Disease—CREBBP—salivary gland cancer	8.98e-05	0.000113	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PHGDH—salivary gland cancer	8.98e-05	0.000113	CbGpPWpGaD
Gefitinib—EGFR—Immune System—FOXO3—salivary gland cancer	8.93e-05	0.000112	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—CDH1—salivary gland cancer	8.86e-05	0.000112	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—MAP2K2—salivary gland cancer	8.78e-05	0.000111	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—PTEN—salivary gland cancer	8.71e-05	0.00011	CbGpPWpGaD
Gefitinib—ALB—Metabolism—ST3GAL4—salivary gland cancer	8.64e-05	0.000109	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—FOXO3—salivary gland cancer	8.63e-05	0.000109	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—AQP1—salivary gland cancer	8.61e-05	0.000108	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—MAP2K2—salivary gland cancer	8.47e-05	0.000107	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—PTEN—salivary gland cancer	8.42e-05	0.000106	CbGpPWpGaD
Gefitinib—ERBB3—Innate Immune System—PIK3CA—salivary gland cancer	8.42e-05	0.000106	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—salivary gland cancer	8.41e-05	0.000106	CbGpPWpGaD
Gefitinib—ABCG2—Transmembrane transport of small molecules—CREBBP—salivary gland cancer	8.35e-05	0.000105	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—EP300—salivary gland cancer	8.31e-05	0.000105	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—CREBBP—salivary gland cancer	8.26e-05	0.000104	CbGpPWpGaD
Gefitinib—EGFR—Disease—FOXO3—salivary gland cancer	8.24e-05	0.000104	CbGpPWpGaD
Gefitinib—EGFR—Signaling by NGF—PIK3CA—salivary gland cancer	8.21e-05	0.000103	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—MAML2—salivary gland cancer	8.18e-05	0.000103	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—salivary gland cancer	8.12e-05	0.000102	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—CREBBP—salivary gland cancer	8.1e-05	0.000102	CbGpPWpGaD
Gefitinib—ERBB3—Adaptive Immune System—PIK3CA—salivary gland cancer	8.08e-05	0.000102	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PHGDH—salivary gland cancer	8.06e-05	0.000102	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—CDH1—salivary gland cancer	8.04e-05	0.000101	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—EP300—salivary gland cancer	8.03e-05	0.000101	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—MAP2K2—salivary gland cancer	7.98e-05	0.000101	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PHGDH—salivary gland cancer	7.86e-05	9.91e-05	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—CCND1—salivary gland cancer	7.85e-05	9.89e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—AQP1—salivary gland cancer	7.85e-05	9.88e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ISYNA1—salivary gland cancer	7.84e-05	9.88e-05	CbGpPWpGaD
Gefitinib—ERBB3—Innate Immune System—HRAS—salivary gland cancer	7.79e-05	9.81e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—ST3GAL4—salivary gland cancer	7.76e-05	9.77e-05	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—salivary gland cancer	7.74e-05	9.75e-05	CbGpPWpGaD
Gefitinib—MKNK1—Disease—PIK3CA—salivary gland cancer	7.64e-05	9.62e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by NGF—HRAS—salivary gland cancer	7.6e-05	9.57e-05	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—PTEN—salivary gland cancer	7.58e-05	9.55e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—ST3GAL4—salivary gland cancer	7.57e-05	9.54e-05	CbGpPWpGaD
Gefitinib—ERBB3—Adaptive Immune System—HRAS—salivary gland cancer	7.48e-05	9.42e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PHGDH—salivary gland cancer	7.41e-05	9.34e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PHGDH—salivary gland cancer	7.35e-05	9.26e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—MAP2K2—salivary gland cancer	7.29e-05	9.18e-05	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—EP300—salivary gland cancer	7.23e-05	9.11e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—NUP62—salivary gland cancer	7.22e-05	9.1e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—NOTCH1—salivary gland cancer	7.2e-05	9.07e-05	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—EP300—salivary gland cancer	7.17e-05	9.03e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—VCAN—salivary gland cancer	7.17e-05	9.03e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—ST3GAL4—salivary gland cancer	7.13e-05	8.99e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—ST3GAL4—salivary gland cancer	7.07e-05	8.91e-05	CbGpPWpGaD
Gefitinib—MKNK1—Disease—HRAS—salivary gland cancer	7.07e-05	8.9e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—MAP2K2—salivary gland cancer	7.05e-05	8.88e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—AQP1—salivary gland cancer	7.04e-05	8.87e-05	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—PIK3CA—salivary gland cancer	7.01e-05	8.83e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—JAG1—salivary gland cancer	6.99e-05	8.8e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—FGFR4—salivary gland cancer	6.96e-05	8.76e-05	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—PTEN—salivary gland cancer	6.95e-05	8.75e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—NOTCH1—salivary gland cancer	6.94e-05	8.74e-05	CbGpPWpGaD
Gefitinib—EGFR—Axon guidance—HRAS—salivary gland cancer	6.88e-05	8.66e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—AQP1—salivary gland cancer	6.87e-05	8.66e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—FBXW7—salivary gland cancer	6.84e-05	8.62e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—NUP62—salivary gland cancer	6.83e-05	8.6e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—VCAN—salivary gland cancer	6.77e-05	8.53e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—MAP2K2—salivary gland cancer	6.73e-05	8.48e-05	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—PTEN—salivary gland cancer	6.64e-05	8.37e-05	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—EP300—salivary gland cancer	6.63e-05	8.35e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—CREBBP—salivary gland cancer	6.53e-05	8.22e-05	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—HRAS—salivary gland cancer	6.48e-05	8.17e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—AQP1—salivary gland cancer	6.48e-05	8.16e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—AQP1—salivary gland cancer	6.42e-05	8.09e-05	CbGpPWpGaD
Gefitinib—ERBB3—Disease—PTEN—salivary gland cancer	6.41e-05	8.08e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—MARCKS—salivary gland cancer	6.39e-05	8.05e-05	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—PTEN—salivary gland cancer	6.38e-05	8.03e-05	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—EP300—salivary gland cancer	6.33e-05	7.98e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—CREBBP—salivary gland cancer	6.29e-05	7.92e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—NUP62—salivary gland cancer	6.22e-05	7.84e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—VCAN—salivary gland cancer	6.17e-05	7.78e-05	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—PIK3CA—salivary gland cancer	6.15e-05	7.74e-05	CbGpPWpGaD
Gefitinib—ERBB3—Disease—EP300—salivary gland cancer	6.12e-05	7.71e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—CCND1—salivary gland cancer	6.11e-05	7.69e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—CREBBP—salivary gland cancer	5.95e-05	7.5e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PYGB—salivary gland cancer	5.94e-05	7.49e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism of lipids and lipoproteins—CREBBP—salivary gland cancer	5.94e-05	7.49e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—PIK3CA—salivary gland cancer	5.94e-05	7.48e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—PTEN—salivary gland cancer	5.9e-05	7.43e-05	CbGpPWpGaD
Gefitinib—ALB—Platelet activation, signaling and aggregation—PIK3CA—salivary gland cancer	5.82e-05	7.33e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—PTEN—salivary gland cancer	5.78e-05	7.29e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—NOTCH1—salivary gland cancer	5.78e-05	7.28e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—FOXO3—salivary gland cancer	5.77e-05	7.27e-05	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—salivary gland cancer	5.73e-05	7.21e-05	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—HRAS—salivary gland cancer	5.69e-05	7.17e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—EP300—salivary gland cancer	5.62e-05	7.08e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—NUP62—salivary gland cancer	5.59e-05	7.04e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—VCAN—salivary gland cancer	5.54e-05	6.98e-05	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—salivary gland cancer	5.54e-05	6.98e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—EP300—salivary gland cancer	5.52e-05	6.95e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—NOTCH1—salivary gland cancer	5.52e-05	6.95e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—HRAS—salivary gland cancer	5.5e-05	6.92e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—NUP62—salivary gland cancer	5.45e-05	6.87e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism of lipids and lipoproteins—CREBBP—salivary gland cancer	5.42e-05	6.82e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—CREBBP—salivary gland cancer	5.42e-05	6.82e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—VCAN—salivary gland cancer	5.41e-05	6.81e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—CDH1—salivary gland cancer	5.38e-05	6.77e-05	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—PIK3CA—salivary gland cancer	5.35e-05	6.74e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—CREBBP—salivary gland cancer	5.24e-05	6.6e-05	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—TP53—salivary gland cancer	5.17e-05	6.52e-05	CbGpPWpGaD
Gefitinib—ALB—Transmembrane transport of small molecules—CREBBP—salivary gland cancer	5.15e-05	6.49e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—NUP62—salivary gland cancer	5.14e-05	6.47e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—VCAN—salivary gland cancer	5.1e-05	6.42e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—NUP62—salivary gland cancer	5.09e-05	6.42e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—VCAN—salivary gland cancer	5.05e-05	6.36e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—CREBBP—salivary gland cancer	5e-05	6.3e-05	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—HRAS—salivary gland cancer	4.95e-05	6.23e-05	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—HRAS—salivary gland cancer	4.91e-05	6.18e-05	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—PIK3CA—salivary gland cancer	4.9e-05	6.17e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—salivary gland cancer	4.86e-05	6.13e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PHGDH—salivary gland cancer	4.85e-05	6.1e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—CCND1—salivary gland cancer	4.83e-05	6.08e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—MAP2K2—salivary gland cancer	4.71e-05	5.94e-05	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—PIK3CA—salivary gland cancer	4.69e-05	5.9e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ST3GAL4—salivary gland cancer	4.66e-05	5.88e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—PTEN—salivary gland cancer	4.66e-05	5.87e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—CCND1—salivary gland cancer	4.65e-05	5.86e-05	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—HRAS—salivary gland cancer	4.53e-05	5.71e-05	CbGpPWpGaD
Gefitinib—ERBB3—Disease—PIK3CA—salivary gland cancer	4.53e-05	5.7e-05	CbGpPWpGaD
Gefitinib—ABCB1—Transmembrane transport of small molecules—CREBBP—salivary gland cancer	4.51e-05	5.69e-05	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—PIK3CA—salivary gland cancer	4.5e-05	5.67e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—PTEN—salivary gland cancer	4.49e-05	5.66e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—EP300—salivary gland cancer	4.44e-05	5.6e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—salivary gland cancer	4.43e-05	5.59e-05	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—HRAS—salivary gland cancer	4.33e-05	5.46e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—EP300—salivary gland cancer	4.28e-05	5.4e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—salivary gland cancer	4.24e-05	5.35e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—AQP1—salivary gland cancer	4.24e-05	5.34e-05	CbGpPWpGaD
Gefitinib—ERBB3—Disease—HRAS—salivary gland cancer	4.19e-05	5.27e-05	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—HRAS—salivary gland cancer	4.16e-05	5.24e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—PIK3CA—salivary gland cancer	4.16e-05	5.24e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—PIK3CA—salivary gland cancer	4.08e-05	5.14e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—EP300—salivary gland cancer	4.05e-05	5.11e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism of lipids and lipoproteins—EP300—salivary gland cancer	4.05e-05	5.1e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—TP53—salivary gland cancer	4.02e-05	5.07e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—CREBBP—salivary gland cancer	3.91e-05	4.93e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—CCND1—salivary gland cancer	3.87e-05	4.88e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism of lipids and lipoproteins—PTEN—salivary gland cancer	3.87e-05	4.87e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—PTEN—salivary gland cancer	3.87e-05	4.87e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—NOTCH1—salivary gland cancer	3.86e-05	4.87e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—HRAS—salivary gland cancer	3.85e-05	4.85e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—HRAS—salivary gland cancer	3.78e-05	4.76e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—PTEN—salivary gland cancer	3.74e-05	4.71e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism of lipids and lipoproteins—EP300—salivary gland cancer	3.69e-05	4.65e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—EP300—salivary gland cancer	3.69e-05	4.65e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—PTEN—salivary gland cancer	3.57e-05	4.5e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—EP300—salivary gland cancer	3.57e-05	4.49e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CREBBP—salivary gland cancer	3.5e-05	4.41e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—salivary gland cancer	3.47e-05	4.37e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—EP300—salivary gland cancer	3.41e-05	4.29e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—NUP62—salivary gland cancer	3.36e-05	4.23e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—VCAN—salivary gland cancer	3.33e-05	4.2e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—EP300—salivary gland cancer	3.31e-05	4.17e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—PIK3CA—salivary gland cancer	3.29e-05	4.14e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—TP53—salivary gland cancer	3.18e-05	4.01e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—PIK3CA—salivary gland cancer	3.17e-05	3.99e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—salivary gland cancer	3.17e-05	3.99e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—TP53—salivary gland cancer	3.07e-05	3.86e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—HRAS—salivary gland cancer	3.04e-05	3.83e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—EP300—salivary gland cancer	3.02e-05	3.8e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—PIK3CA—salivary gland cancer	3e-05	3.78e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—salivary gland cancer	2.99e-05	3.77e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—PIK3CA—salivary gland cancer	2.99e-05	3.76e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—HRAS—salivary gland cancer	2.93e-05	3.69e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—TP53—salivary gland cancer	2.9e-05	3.65e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—CREBBP—salivary gland cancer	2.8e-05	3.53e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—PTEN—salivary gland cancer	2.79e-05	3.52e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—HRAS—salivary gland cancer	2.77e-05	3.49e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—HRAS—salivary gland cancer	2.76e-05	3.48e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism of lipids and lipoproteins—PIK3CA—salivary gland cancer	2.73e-05	3.44e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—PIK3CA—salivary gland cancer	2.73e-05	3.44e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—EP300—salivary gland cancer	2.66e-05	3.35e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—CREBBP—salivary gland cancer	2.65e-05	3.33e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—PIK3CA—salivary gland cancer	2.64e-05	3.32e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CCND1—salivary gland cancer	2.59e-05	3.26e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—TP53—salivary gland cancer	2.55e-05	3.22e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—HRAS—salivary gland cancer	2.52e-05	3.18e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—PIK3CA—salivary gland cancer	2.52e-05	3.17e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—PTEN—salivary gland cancer	2.5e-05	3.15e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—salivary gland cancer	2.45e-05	3.09e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—HRAS—salivary gland cancer	2.44e-05	3.08e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—CREBBP—salivary gland cancer	2.41e-05	3.04e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—EP300—salivary gland cancer	2.38e-05	3e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—HRAS—salivary gland cancer	2.33e-05	2.94e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—salivary gland cancer	2.23e-05	2.81e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—CREBBP—salivary gland cancer	2.17e-05	2.73e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—CREBBP—salivary gland cancer	2.11e-05	2.66e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PTEN—salivary gland cancer	2e-05	2.52e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—CREBBP—salivary gland cancer	1.99e-05	2.51e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—CREBBP—salivary gland cancer	1.97e-05	2.49e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—PIK3CA—salivary gland cancer	1.97e-05	2.48e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—EP300—salivary gland cancer	1.91e-05	2.4e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PTEN—salivary gland cancer	1.89e-05	2.38e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—EP300—salivary gland cancer	1.8e-05	2.27e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—PIK3CA—salivary gland cancer	1.76e-05	2.22e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PTEN—salivary gland cancer	1.72e-05	2.17e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—TP53—salivary gland cancer	1.71e-05	2.15e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—EP300—salivary gland cancer	1.64e-05	2.07e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—HRAS—salivary gland cancer	1.63e-05	2.06e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PTEN—salivary gland cancer	1.55e-05	1.95e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PTEN—salivary gland cancer	1.51e-05	1.9e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—EP300—salivary gland cancer	1.47e-05	1.86e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—EP300—salivary gland cancer	1.44e-05	1.81e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PTEN—salivary gland cancer	1.42e-05	1.79e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PIK3CA—salivary gland cancer	1.41e-05	1.78e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PTEN—salivary gland cancer	1.41e-05	1.78e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—EP300—salivary gland cancer	1.36e-05	1.71e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—EP300—salivary gland cancer	1.34e-05	1.69e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PIK3CA—salivary gland cancer	1.33e-05	1.68e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CREBBP—salivary gland cancer	1.3e-05	1.64e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PIK3CA—salivary gland cancer	1.22e-05	1.53e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PIK3CA—salivary gland cancer	1.09e-05	1.37e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PIK3CA—salivary gland cancer	1.06e-05	1.34e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PIK3CA—salivary gland cancer	1e-05	1.26e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PIK3CA—salivary gland cancer	9.95e-06	1.25e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PTEN—salivary gland cancer	9.3e-06	1.17e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—EP300—salivary gland cancer	8.87e-06	1.12e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PIK3CA—salivary gland cancer	6.56e-06	8.27e-06	CbGpPWpGaD
